BreStem Therapeutics
Phase 1BreStem is a clinical stage biotech company working to fight deadly lung diseases through stem cell and exosome therapies. The company’s lead candidate BRS101(autologous lung spheroid cells) has gained FDA approval as the world’s first IND using intrinsic lung-derived cells to treat pulmonary conditions.
Founded
2018
Focus
Cell & Gene Therapy
About
BreStem is a clinical stage biotech company working to fight deadly lung diseases through stem cell and exosome therapies. The company’s lead candidate BRS101(autologous lung spheroid cells) has gained FDA approval as the world’s first IND using intrinsic lung-derived cells to treat pulmonary conditions.
Funding History
2Total raised: $14.5M
Series A$12MUndisclosedMar 15, 2023
Seed$2.5MUndisclosedJun 15, 2021
Company Info
TypePrivate
Founded2018
LocationSan Diego, United States
StagePhase 1
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile